Display options
Cite
Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2007;123(2):138-46doi: 10.1016/j.ijcard.2006.12.001.
Ahmed, A., Pitt, B., Rahimtoola, S. H., Waagstein, F., White, M., Love, T. E., & Braunwald, E. (2008). Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. International journal of cardiology, 123(2), 138-46. https://doi.org/10.1016/j.ijcard.2006.12.001
Ahmed, Ali, et al. "Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial." International journal of cardiology vol. 123,2 (2008): 138-46. doi: https://doi.org/10.1016/j.ijcard.2006.12.001
Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008 Jan 11;123(2):138-46. doi: 10.1016/j.ijcard.2006.12.001. Epub 2007 Mar 23. PMID: 17382417; PMCID: PMC2474767.
Copy Download .nbib Format: NLM
Share it on

Int J Cardiol. 2008 Jan 11;123(2):138-46. doi: 10.1016/j.ijcard.2006.12.001. Epub 2007 Mar 23.

Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial.

International journal of cardiology

Ali Ahmed, Bertram Pitt, Shahbudin H Rahimtoola, Finn Waagstein, Michel White, Thomas E Love, Eugene Braunwald

Affiliations

  1. University of Alabama at Birmingham, 1530 3rd Ave South, CH-19, Ste-219 and VA Medical Center, Birmingham, AL 35294-2041, USA. [email protected]

PMID: 17382417 PMCID: PMC2474767 DOI: 10.1016/j.ijcard.2006.12.001

Abstract

BACKGROUND: In heart failure (HF), digoxin at low serum digoxin concentrations (SDC) reduces all-cause mortality and HF hospitalizations. However, the effects of digoxin on other cause-specific outcomes have not been studied in a propensity-matched cohort.

METHODS: The Digitalis Investigation Group trial, conducted during 1991-1993, enrolled 7788 ambulatory chronic HF patients. This analysis focuses on 4843 patients: 982 receiving digoxin with low (0.5-0.9 ng/ml) SDC at one month, and 3861 receiving placebo and alive at one month. Propensity scores for low SDC, calculated using a non-parsimonious multivariable logistic regression model, were used to match 982 low-SDC patients with 982 placebo patients. Matched Cox regression analyses were used to determine the effect of digoxin at low SDC on outcomes.

RESULTS: All-cause mortality occurred in 315 placebo (rate, 1071/10,000 person-years) and 288 low-SDC digoxin (rate, 871/10,000 person-years) patients, respectively, during 2940 and 3305 years of follow up (hazard ratio {HR}, 0.81, 95% confidence interval {CI}, 0.68-0.98; p=0.028). Cardiovascular hospitalizations occurred in 493 placebo (2359/10,000 person-year) and 471 low-SDC digoxin (1963/10,000 person-year) patients, respectively during 2090 and 2399 years of follow up (HR, 0.82, 95% CI, 0.70-0.95; P=0.010). Low-SDC digoxin to placebo HR (95%CI) for HF mortality and HF hospitalizations were respectively, 0.65 (0.45-0.92; P=0.015) and 0.63 (0.52-0.77; P<0.0001). Low-dose digoxin (< or = 0.125 mg/day) was the strongest independent predictor of low SDC (adjusted odd ratio, 2.07, 95% CI 1.54-2.80).

CONCLUSIONS: Digoxin at low SDC significantly reduced mortality and hospitalizations in ambulatory chronic systolic and diastolic HF patients.

References

  1. N Engl J Med. 1997 Feb 20;336(8):525-33 - PubMed
  2. Control Clin Trials. 1996 Feb;17(1):77-97 - PubMed
  3. Ann Intern Med. 1999 Mar 16;130(6):461-70 - PubMed
  4. N Engl J Med. 1999 Sep 2;341(10):709-17 - PubMed
  5. Lancet. 2005 Jan 8-14;365(9454):176-86 - PubMed
  6. J Card Fail. 2005 Mar;11(2):87-90 - PubMed
  7. Eur Heart J. 2005 Jun;26(11):1115-40 - PubMed
  8. Arch Intern Med. 2005 Jul 11;165(13):1469-77 - PubMed
  9. J Am Coll Cardiol. 2005 Aug 2;46(3):497-504 - PubMed
  10. J Am Coll Cardiol. 2005 Sep 20;46(6):e1-82 - PubMed
  11. Eur Heart J. 2006 Jan;27(2):178-86 - PubMed
  12. Eur Heart J. 2006 Jan;27(2):127-9 - PubMed
  13. Can J Cardiol. 2006 Jan;22(1):23-45 - PubMed
  14. J Card Fail. 2006 Feb;12(1):10-38 - PubMed
  15. Circulation. 2006 May 30;113(21):2556-64 - PubMed
  16. Eur Heart J. 2006 Jun;27(12):1431-9 - PubMed
  17. J Card Fail. 2006 Jun;12(5):347-8 - PubMed
  18. Circulation. 2006 Aug 1;114(5):397-403 - PubMed
  19. Int J Clin Pharmacol Ther Toxicol. 1980 Jul;18(7):322-3 - PubMed
  20. Circ Res. 1979 Jan;44(1):8-15 - PubMed
  21. Stat Med. 1998 Oct 15;17(19):2265-81 - PubMed
  22. Am J Med. 1983 Sep;75(3):445-7 - PubMed
  23. Biometrics. 1985 Mar;41(1):103-16 - PubMed
  24. Circulation. 1989 Jul;80(1):65-77 - PubMed
  25. N Engl J Med. 1969 Nov 27;281(22):1212-6 - PubMed
  26. Am J Physiol. 1972 Jun;222(6):1398-405 - PubMed
  27. Am J Cardiol. 2000 Nov 1;86(9):1032-5, A10-1 - PubMed
  28. J Clin Epidemiol. 2001 Apr;54(4):387-98 - PubMed
  29. JAMA. 2002 Jun 19;287(23):3130-2 - PubMed
  30. N Engl J Med. 2002 Oct 31;347(18):1403-11 - PubMed
  31. Circulation. 2004 Jun 22;109(24):2942-6 - PubMed
  32. Circulation. 1991 Nov;84(5):2181-6 - PubMed
  33. Ann Intern Med. 1993 Feb 1;118(3):201-10 - PubMed

Substances

MeSH terms

Publication Types

Grant support